Flawed evidence should not derail sound policy: The case remains strong for population-wide sodium reduction

American Journal of Hypertension

Volumn 26, Issue 10, 2013, Pages 1183-1186

  Appel, Lawrence J ^a,b,c   Whelton, Paul K ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; RENIN; SODIUM;

CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; ELEVATED BLOOD PRESSURE; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MEDICAL SOCIETY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SODIUM INTAKE; SODIUM RESTRICTION; SODIUM URINE LEVEL; STEADY STATE; UNITED STATES; URINARY EXCRETION;

CARDIOVASCULAR DISEASES; HEALTH POLICY; HUMANS; INSTITUTE OF MEDICINE (U.S.); RECOMMENDED DIETARY ALLOWANCES; SODIUM; SODIUM, DIETARY; UNITED STATES;

EID: 84890109338     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt147     Document Type: Review

References (34)

1. Institute of Medicine. Sodium Intake in Populations: Assessment of Evidence. National Academies Press: Washington, DC, 2013
2. Kolata G. No benefit seen in sharp limits on salt in diet. New York Times 15 May 2013 http:// www.nytimes.com/2013/05/15/health/panelfinds-no-benefit-in- sharply-restrictingsodium. html?google-editors-picks=true&-r=0
3. Strom BL, Anderson CA, Ix JH. Sodium reduction in populations: Insights from the institute of medicine committee. JAMA 2013; 310:31-32
4. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT, Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, Chen JS, Cheng AT, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi S, Falder G, Farzadfar F, Ferrari A, Finucane MM, Flaxman S, Fowkes FG, Freedman G, Freeman MK, Gakidou E, Ghosh S, Giovannucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, Hoek HW, Hogan A, Hosgood HD, 3rd, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang YH, Khatibzadeh S, Khoo JP, Kok C, Laden F, Lalloo R, Lan Q, Lathlean T, Leasher JL, Leigh J, Li Y, Lin JK, Lipshultz SE, London S, Lozano R, Lu Y, Mak J, Malekzadeh R, Mallinger L, Marcenes W, March L, Marks R, Martin R, McGale P, McGrath J, Mehta S, Mensah GA, Merriman TR, Micha R, Michaud C, Mishra V, Mohd Hanafiah K, Mokdad AA, Morawska L, Mozaffarian D, Murphy T, Naghavi M, Neal B, Nelson PK, Nolla JM, A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2224-2260
5. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365:217-223
6. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913
7. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, Roccella EJ, Stout R, Vallbona C, Winston MC, Karimbakas J, National High Blood Pressure Education Program Coordinating Committee. Primary prevention of hypertension: Clinical and public health advisory from the national high blood pressure education program. JAMA 2002; 288:1882-1888
8. Lloyd-Jones D, Hong Y, Labarthe D, Mozaffarian D, Appel L, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli G, Arnett D, Fonarow G, Ho M, Lauer M, Masoudi F, Robertson RM, Roger V, Schwamm L, Sorlie P, Yancy C, Rosamond W, on behalf of the American Heart Association Stategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovacular health promotion and disease reduction. The American Heart Association's strategic impact goal through 2020 and beyond. Circulation 2010; 121:586-613
9. He FJ, MacGregor GA. A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. J Hum Hypertens 2009; 23:363-384
10. Coxson PG, Cook NR, Joffres M, Hong Y, Orenstein D, Schmidt SM, Bibbins-Domingo K. Mortality benefits from US population-wide reduction in sodium consumption: Projections from 3 modeling approaches. Hypertension 2013; 61:564-570
11. Stolarz-Skrzypek K, Kuznetsova T, Thijs L, Tikhonoff V, Seidlerova J, Richart T, Jin Y, Olszanecka A, Malyutina S, Casiglia E, Filipovsky J, Kawecka-Jaszcz K, Nikitin Y, Staessen JA, European Project on Genes in Hypertension (EPOGH) Investigators. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA 2011; 305:1777-1785
12. O'Donnell MJ, Yusuf S, Mente A, Gao P, Mann JF, Teo K, McQueen M, Sleight P, Sharma AM, Dans A, Probstfield J, Schmieder RE. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA 2011; 306:2229-2238
13. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Water, Potssium, Sodium, Chloride, and Sulfate. National Academies Press: Washington, DC, 2005
14. United States Department of Agriculture, Center for Nutrition Policy and Promotion. United States Dietary Guidelines for Americans, 2010. http://www.dietaryguidelines.gov
15. Paterna S, Gaspare P, Fasullo S, Sarullo FM, Di Pasquale P. Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: Is sodium an old enemy or a new friend? Clin Sci (Lond) 2008; 114:221-230
16. Paterna S, Parrinello G, Cannizzaro S, Fasullo S, Torres D, Sarullo FM, Di Pasquale P. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure. Am J Cardiol 2009; 103:93-102
17. Arcand J, Newton GE. Dietary sodium reduction in heart failure: A challenge to the Cochrane Review. Am J Hypertens 2012; 25:19; author reply 20
18. O'Donnell MJ, Mente A, Smyth A, Yusuf S. Salt intake and cardiovascular disease: Why are the data inconsistent? Eur Heart J 2013; 34:1034-1040
19. Liu K, Dyer AR, Cooper RS, Stamler R, Stamler J. Can overnight urine replace 24-hour urine collection to assess salt intake? Hypertension 1979; 1:529-536
20. Luft FC, Aronoff GR, Sloan RS, Fineberg NS. Intra-and interindividual variability in sodium intake in normal subjects and in patients with renal insufficiency. Am J Kidney Dis 1986; 7:375-380
21. Arcand J, Floras JS, Azevedo E, Mak S, Newton GE, Allard JP. Evaluation of 2 methods for sodium intake assessment in cardiac patients with and without heart failure: The confounding effect of loop diuretics. Am J Clin Nutr 2011; 93:535-541
22. Mann SJ, Gerber LM. Estimation of 24-hour sodium excretion from spot urine samples. J Clin Hypertens (Greenwich) 2010; 12:174-180
23. Ji C, Sykes L, Paul C, Dary O, Legetic B, Campbell NR, Cappuccio FP. Systematic review of studies comparing 24-hour and spot urine collections for estimating population salt intake. Rev Panam Salud Publica 2012; 32:307-315
24. Whelton PK, Appel LJ, Sacco RL, Anderson CA, Antman EM, Campbell N, Dunbar SB, Frohlich ED, Hall JE, Jessup M, Labarthe DR, Macgregor GA, Sacks FM, Stamler J, Vafiadis DK, Van Horn LV. Sodium, blood pressure, and cardiovascular disease: Further evidence supporting the American Heart Association sodium reduction recommendations. Circulation 2012; 126: 2880-2889
25. Maillot M, Monsivais P, Drewnowski A. Food pattern modeling shows that the 2010 dietary guidelines for sodium and potassium cannot be met simultaneously. Nutr Res 2013; 33:188-194
26. Trials of Hypertension Prevention Research Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA 1992; 267:1213-1220
27. Trials of Hypertension Prevention Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997; 157:657-667
28. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH, Jr, Kostis JB, Kumanyika S, Lacy CR, Johnson KC, Folmar S, Cutler JA. Sodium reduction and weight loss in the treatment of hypertension in older persons: A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998; 279:839-846
29. Morgan T, Adam W, Gillies A, Wilson M, Morgan G, Carney S. Hypertension treated by salt restriction. Lancet 1978; 1:227-230
30. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: Observational follow-up of the Trials of Hypertension Prevention (TOHP). BMJ 2007; 334:885
31. He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: Meta-analysis of outcome trials. Lancet 2011; 378:380-382
32. Aburto NJ, Ziolkovska A, Hooper L, Elliott P, Cappuccio FP, Meerpohl J. Effect of lower sodium intake on health: Systematic review and meta-analyses. BMJ 2013; 346. doi:10.1136/bmj.f1326
33. Micheel CM, Ball JR, ed. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. http://www.iom.edu/Reports/2010/ Evaluation-of-Biomarkers- and-Surrogate-Endpoints-in-Chronic-Disease.aspx
34. Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med 2012; 31:2973-2984